“dQ&A provides that independent voice to the diabetes discussion and goes out of their way to capture key market segments like Type 1’s, insulin users and pumpers.”
Suggested Articles
FDA Advisory Committee: dQ&A® Panel Members Weigh in on Provention Bio’s Teplizumab
This week, the FDA decided in a 10:7 vote to approve Provention Bio’s teplizumab, a drug that could delay the onset of type 1 diabetes for up to two years for high-risk individuals. Recent clinical trial data suggest…
Implications of Stigma in Diabetes
We recently asked members of the dQ&A US Patient Panel about stigma in diabetes…
COVID Fears Kept One in Five People With Diabetes Away From the Doctor During Pandemic
Results released by dQ&A and the…
